Helmy Eltoukhy

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Diamond, EGFR, Helmy Eltoukhy, Mutation, Prevalence, NSCLC, Survival, Foundation Medicine, Patient, Cancer, Lung cancer, AACR, PACC, TKI, Drug resistance, MD Anderson Cancer Center, Associate professor

CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.

Key Points: 
  • The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
  • The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
  • The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
  • Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Pharmaceutical, Oncology, Data Management, Consumer, Technology, Artificial Intelligence, Health Technology, Data Analytics, Women, Biotechnology, Health, Helmy Eltoukhy, Patient, Neoplasm, Research, AACR, Epigenomics, Breast cancer, MRD

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.
  • Multiple poster sessions will report on the utility of using the Guardant Infinity™ platform across the continuum of cancer care, ranging from predictive histologic subtyping of tumors to cardiac adverse event prediction.
  • Data will also be presented demonstrating strong performance of Guardant Reveal for minimal residual disease (MRD) detection in breast cancer, allowing quantification of ctDNA even in early-stage disease without the need for a tissue specimen.
  • “We look forward to sharing new data at AACR, in particular studies demonstrating the potential for epigenomic analysis using the Guardant Infinity platform to advance cancer research,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.

Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine

Retrieved on: 
Wednesday, March 13, 2024
Health, Oncology, Clinical Trials, Medical Supplies, Harvard Medical School, Colonoscopy, Colorectal cancer, Helmy Eltoukhy, Survival rate, Massachusetts General Hospital, Cancer, Risk, Patient, Ageing, Evaluation, American Cancer Society, Neoplasm, Perception, DNA, MD, Circulating tumor DNA, Hospital, PMA, CRC, Large intestine, Multimedia, FDA, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240313547689/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240313547689/en/
    Shield (TM) from Guardant Health is a blood test for colorectal cancer screening for adults age 45-84 who are at average risk.
  • (Photo: Business Wire)
    “Over 50 million eligible Americans do not get recommended screenings for colorectal cancer, partly because current screening methods are inconvenient or unpleasant,” said AmirAli Talasaz, Guardant Health co-CEO.
  • The Shield test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA).
  • One recent study showed that CRC screening rates tripled among adults who had declined prior CRC screening when they were offered Shield.

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, March 6, 2024
Oncology, Professional Services, Health, Data Analytics, Technology, Software, Biotechnology, Inducement, RSU, Compensated emancipation, Employment, Helmy Eltoukhy

The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.
  • The stock options are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option award agreement covering the grant.

Box Reports Fiscal Fourth Quarter and Fiscal Year 2024 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Software, Technology, Networks, Apps, Applications, Cloud, Regulation, Air force, Investment, News, Part, Growth, Parent, Regulation Fair Disclosure, Novo Nordisk, Organization, Helmy Eltoukhy, FX, Marketing, Disclosure, RPO, Square, GAAP, Security (finance), Child, EPS, Microsoft, Environment, ID, Cosmetic industry, Hormel Foods, CFO, Japanese yen, FDA, Privacy, Video game

Box, Inc. (NYSE:BOX), the leading Content Cloud, today announced preliminary financial results for the fourth quarter and fiscal year 2024, which ended January 31, 2024.

Key Points: 
  • Box, Inc. (NYSE:BOX), the leading Content Cloud, today announced preliminary financial results for the fourth quarter and fiscal year 2024, which ended January 31, 2024.
  • Non-GAAP operating income in the fourth quarter of fiscal year 2024 was $70.1 million, or 26.7% of revenue.
  • Non-GAAP diluted net income per share attributable to common stockholders in the fourth quarter of fiscal year 2024 was $0.42.
  • Non-GAAP free cash flow in the fourth quarter of fiscal year 2024 was $81.8 million, a 10% increase from non-GAAP free cash flow of $74.7 million in the fourth quarter of fiscal year 2023.

New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap

Retrieved on: 
Friday, March 1, 2024
Biotechnology, Health Technology, Health, Oncology, Anxiety, Education, Colorectal cancer, Colonoscopy, Physician, FDA, Pain, Gastroenterology, Colorectal Cancer Alliance, CRC, Perception, Survival rate, Fear, Patient, The Harris Poll, Helmy Eltoukhy, Cancer, Online shopping

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new survey showing patients and physicians overwhelmingly agree that blood-based testing could help close the colorectal cancer (CRC) screening gap by offering a more pleasant and convenient option.
  • The survey polled 1,000 American adults age 45-84, along with 351 physicians (250 primary care providers and 101 gastroenterologists).
  • In the United States, CRC screening guidelines recommend that all people of average risk begin screening starting at age 45.
  • Ultimately, 96% of all physicians surveyed would recommend an FDA-approved blood test to their patients for CRC screening.

Litify Announces Record Performance In 2023

Retrieved on: 
Wednesday, February 28, 2024
Venture Capital, Legal, Software, Insurance, Artificial Intelligence, Professional Services, Technology, Apps, Applications, Legal technology, Fortune 500, Growth, Automation, Case management, Helmy Eltoukhy, Online shopping

Litify , the all-in-one legal platform for law firms and in-house legal teams, today announced record company performance in 2023.

Key Points: 
  • Litify , the all-in-one legal platform for law firms and in-house legal teams, today announced record company performance in 2023.
  • “2023 was a standout year for Litify and is a testament to the way our clients are advancing the legal industry.
  • I’m impressed by their results on our platform — and grateful that they choose Litify to transform their operations,” said Litify CEO Curtis Brewer .
  • In 2023, Litify clients grew an average of 20% — and up to 400% — while using the platform.

BostonGene Bolsters Leadership Team to Accelerate Innovation and Growth

Retrieved on: 
Thursday, February 22, 2024
Health, Genetics, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Wake Forest University, Cambia Health Solutions, Senior, Doctor of Philosophy, RingCentral, Small business, Georgetown University, Medical director, Record, Molecular medicine, Drug development, Hospital, Radiology, Beyond Meat, MBA, MGH, Stanford University, University, Pathology, Associate, Patient, Intuit, Goldman Sachs, RPX, Massachusetts General Hospital, Harvard Medical School, Helmy Eltoukhy, Cancer, Management

"On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.

Key Points: 
  • "On behalf of the BostonGene Board of Directors, I am thrilled to welcome Joe, Mark, and Ned to our team," said Andrew Feinberg, President and CEO of BostonGene.
  • Dr. Lennerz received an MD and a PhD in molecular medicine from the University of Erlangen, Germany.
  • "I am delighted to join BostonGene at such a pivotal moment in its trajectory.
  • In addition to BostonGene, Ned is a board member at RingCentral and Beyond Meat.

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Retrieved on: 
Thursday, February 22, 2024
Software, Professional Services, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Data Analytics, Biotechnology, FDA, Health, ASPS, Acquisition, Joint venture, PMA, Forecasting, Marketing, Growth, CRC, LDT, GAAP, Webcast, Net, Helmy Eltoukhy, Research, Depreciation, Shield, Pharmaceutical industry

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.
  • Development services and other revenue was $12.9 million for the fourth quarter of 2023, compared to $13.1 million for the corresponding prior year period.
  • Precision oncology gross margin was 60% in the fourth quarter of 2023, as compared to 62% in the prior year period.
  • Guardant Health will host a conference call to discuss the fourth quarter and full year 2023 financial results after market close on Thursday, February 22, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Helmy Eltoukhy, FDA, Bank statement, Colorectal cancer

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023.
  • Cash, cash equivalents and marketable debt securities were $1.2 billion as of December 31, 2023.
  • “We finished the year strong with revenue growth of 25% in 2023, driven by robust clinical volume growth.
  • Guardant Health plans to report its fourth quarter and full year audited financial results for the period ended December 31, 2023, during its February 2024 earnings call.